Credit Suisse Group set a €71.00 ($82.56) price objective on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research note published on Thursday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
Other equities research analysts have also recently issued reports about the company. HSBC set a €101.00 ($117.44) target price on Grenke and gave the stock a buy rating in a research note on Thursday, April 25th. Jefferies Financial Group reiterated a buy rating and set a GBX 99 ($1.29) target price on shares of in a research note on Friday, June 28th. Barclays reiterated a hold rating and set a $14.00 target price on shares of MACOM Technology Solutions in a research note on Thursday, June 20th. Morgan Stanley lifted their target price on WPP from GBX 1,025 ($13.39) to GBX 1,060 ($13.85) and gave the stock an equal weight rating in a research note on Wednesday, July 17th. Finally, UBS Group lifted their target price on LyondellBasell Industries from $86.00 to $89.00 and gave the stock a neutral rating in a research note on Thursday, July 11th. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of Buy and a consensus target price of €82.57 ($96.01).
Shares of ETR:FME opened at €67.00 ($77.91) on Thursday. The company has a current ratio of 1.02, a quick ratio of 0.67 and a debt-to-equity ratio of 100.05. The company’s fifty day moving average is €68.38. Fresenius Medical Care AG & Co. KGaA has a 1-year low of €55.44 ($64.47) and a 1-year high of €91.74 ($106.67). The company has a market cap of $20.45 billion and a PE ratio of 10.43.
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Recommended Story: Understanding Options Trading
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.